IntelliCyt Corporation develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. IntelliCyt's proprietary technologies, instrumentation, assays and software products address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology, and life science research.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/06/13 | $8,000,000 |
Arboretum Ventures New Mexico Community Capital Prolog Ventures Verge Fund | undisclosed | |
| 10/23/15 | $7,400,000 |
Arboretum Ventures New Mexico Community Capital Oxford Finance Prolog Ventures Verge Fund | undisclosed |
